2021 research period for North America is officially open
March 24, 2021
Research team is now accepting firm submissions, due June 1
US
Hatch-Waxman Patent Litigation (Generic)
| Hatch-Waxman Patent Litigation (Generic) — Highly Recommended |
|---|
| Goodwin Procter |
| Knobbe Martens |
| Rakoczy Molino Mazzochi Siwik |
| Sterne Kessler Goldstein & Fox |
| Wilson Sonsini Goodrich & Rosati |
| Winston & Strawn |
| Hatch-Waxman Patent Litigation (Generic) — Recommended |
|---|
| Axinn Veltrop & Harkrider |
| Greenberg Traurig |
| Morrison & Foerster |
| Perkins Coie |
| Robins Kaplan |
| Rothwell Figg Ernst & Manbeck |
| Taft Stettinius & Hollister |
| Willkie Farr & Gallagher |
Patent Prosecution
| Lawyer | Section | Practice Area | Location |
|---|---|---|---|
| Anstaett, David L | Intellectual Property | Patent Strategy & Management, Hatch-Waxman Patent Litigation | Madison |
| Bloodworth, Shannon M | Intellectual Property | Patent Strategy & Management, General Patent Litigation, Hatch-Waxman Patent Litigation | Washington, D.C. |
| Parker, Paul | Intellectual Property | Patent Prosecution, Patent Strategy & Management | Seattle |
| White, Brandon | Intellectual Property | General Patent Litigation, Hatch-Waxman Patent Litigation | Washington, D.C. |
| Wicker, Mark R | Financial & Corporate | Licensing & Collaboration | San Diego |
| Wise, Michael | Intellectual Property | Patent Prosecution, Patent Strategy & Management, General Patent Litigation | Los Angeles |
| , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} |
Intellectual Property
Perkins Coie
West Coast-based firm Perkins Coie is nationally ranked for its practices focused on generic Hatch-Waxman litigation and patent prosecution. The firm represents a diverse mix of clients in the life sciences sector, including companies in the pharmaceutical, biotechnology and medical device areas. For a significant streak represent generic companies in novel pharmaceutical litigations, Perkins Coie was awarded Hatch-Waxman Litigation Firm of the Year for Generics in 2020.
"Our view is the specific attorney makes all of the difference, and Michael Wise at Perkins Coie has consistently created value for our firm through his work," a client says about the firm's life sciences industry group chair. Wise specializes in patent prosecution, portfolio development and litigation in the life sciences sector. He recently assisted patent prosecution client Eloxx Pharmaceuticals in IP diligence related to its $30 million common stock offering. Wise also continues to represent City of Hope in connection with patent filing and prosecution. Seattle-based Paul Parker is chair of the firm's medical device industry group. He receives repeated praise from peers in the space for his work counseling companies on their med tech portfolios.
Shannon Bloodworth co-chairs the firm's IP practice group, and is one of the country's leading litigators for Hatch-Waxman disputes. She and Brandon White acted as lead in the newsworthy pharmaceutical dispute Biogen v Mylan. The firm’s client Mylan received a favorable trial outcome when a West Virginia judge found 13 claims covering Biogen’s blockbuster Tecfidera drug did not meet written description requirements under Section 112. Bloodworth was shortlisted for a Litigator of the Year award category and the firm won the Generic Hatch-Waxman honor in part due to this matter.